PHARMAESSENTIA CORP.
Area: Pharmaceutical and Medical Devices
Booth No: R207
Website: https://hq.pharmaessentia.com/tw
Exhibitor Profile
Compared with similar drugs on the market, the long-acting, mono-pegylated proline interferon with improved pharmacokinetic properties allowing once every two weeks administration offering improved tolerability and convenience. The marketing authorization for PharmaEssentia’s Ropeginterferon alfa-2b for treatment of Polycythemia Vera (PV) is granted by EMA in February 2019, Taiwan in May 2020 and FDA in November 2021.
Brands
Ropeginterferon alfa-2b
Exhibit Products
Exhibitors you may be interested in
Highest Rated